JP7369819B2 - Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material - Google Patents
Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material Download PDFInfo
- Publication number
- JP7369819B2 JP7369819B2 JP2022058332A JP2022058332A JP7369819B2 JP 7369819 B2 JP7369819 B2 JP 7369819B2 JP 2022058332 A JP2022058332 A JP 2022058332A JP 2022058332 A JP2022058332 A JP 2022058332A JP 7369819 B2 JP7369819 B2 JP 7369819B2
- Authority
- JP
- Japan
- Prior art keywords
- alginate
- solid material
- salt
- sodium
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 37
- 150000003839 salts Chemical class 0.000 title claims description 28
- 235000013305 food Nutrition 0.000 title claims description 16
- 239000011343 solid material Substances 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 235000010408 potassium alginate Nutrition 0.000 claims description 49
- 239000000737 potassium alginate Substances 0.000 claims description 48
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 48
- 239000011734 sodium Substances 0.000 claims description 31
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 27
- 229910052708 sodium Inorganic materials 0.000 claims description 27
- 159000000007 calcium salts Chemical class 0.000 claims description 26
- 235000010407 ammonium alginate Nutrition 0.000 claims description 24
- 239000000728 ammonium alginate Substances 0.000 claims description 24
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 42
- 235000010443 alginic acid Nutrition 0.000 description 11
- 229920000615 alginic acid Polymers 0.000 description 11
- 235000010410 calcium alginate Nutrition 0.000 description 10
- 239000000648 calcium alginate Substances 0.000 description 10
- 229960002681 calcium alginate Drugs 0.000 description 10
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 229960004256 calcium citrate Drugs 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 235000021023 sodium intake Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- -1 ammonium ions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
Description
本発明は、ナトリウム吸着性及び食感に優れたナトリウム吸着性固形状物の製造方法及び該固形状物を含む排塩用食品組成物に関する。 The present invention relates to a method for producing a sodium-adsorbing solid material with excellent sodium-adsorbing properties and texture, and a food composition for discharging salt containing the solid material.
ヒト及び非ヒト動物(例えば、イヌ及びネコ)において、ナトリウム(塩分)の過剰摂取が、高血圧及びこれと関連する他の循環器系疾患に影響を与えることが知られている。ナトリウムの過剰摂取による健康障害を予防又は改善する方法として、例えば、調味料としての食塩の添加量を控える等、食事中の塩分を低減することが行われている。しかし、塩味は食品の味覚として重要であり、食事中の塩分の低減は、食品の嗜好性をも低減させることになる。そのため、単に食事中の塩分を低減することは、持続性の観点から必ずしも容易ではない。 Excessive sodium (salt) intake is known to affect hypertension and other related cardiovascular diseases in humans and non-human animals (eg, dogs and cats). BACKGROUND ART As a method for preventing or improving health problems caused by excessive intake of sodium, for example, reducing the amount of salt in meals is carried out, such as by reducing the amount of salt added as a seasoning. However, salty taste is important as a taste of foods, and reducing salt in meals also reduces the palatability of foods. Therefore, simply reducing the salt content in the diet is not necessarily easy from a sustainability perspective.
食品の嗜好性を維持し、且つナトリウムの過剰摂取による健康障害を予防又は改善するために、摂取したナトリウムの体外への排出を促進させる成分の開発が進められている。このようなナトリウムの排出を促進する成分として、アルギン酸塩類が知られている(特許文献1~3)。 In order to maintain the palatability of foods and prevent or improve health disorders caused by excessive sodium intake, efforts are being made to develop components that promote the excretion of ingested sodium from the body. Alginates are known as components that promote the excretion of sodium (Patent Documents 1 to 3).
ナトリウムの過剰摂取による健康障害を予防又は改善するためには、より優れたナトリウム排出能を有する成分の開発が求められている。このような成分は経口投与が可能であることが望ましい。これに関して、経口投与される成分の味及び食感が悪いと、ヒト及び非ヒト動物はかかる成分の摂取を忌避するおそれがある。よって、このような成分は味及び食感に優れていることも求められる。この点について、既存のアルギン酸塩類では、口の中でねちゃつく等、食感が十分と言えない場合があった。 In order to prevent or ameliorate health disorders caused by excessive intake of sodium, there is a need for the development of ingredients with better sodium excretion ability. It is desirable that such ingredients be able to be administered orally. In this regard, if the taste and texture of orally administered ingredients are poor, humans and non-human animals may avoid ingesting such ingredients. Therefore, such ingredients are also required to have excellent taste and texture. In this regard, existing alginates sometimes have insufficient texture, such as being sticky in the mouth.
本発明は、ナトリウム吸着性及び食感に優れ、経口投与が容易なナトリウム吸着性固形状物の製造方法及び該固形状物を含む排塩用食品組成物を提供することを目的とする。 An object of the present invention is to provide a method for producing a sodium-adsorbing solid material that has excellent sodium adsorption properties and texture and is easy to administer orally, and a food composition for salt removal containing the solid material.
本発明のナトリウム吸着性固形状物の製造方法は、0.1~5重量%のアルギン酸カリウム又はアルギン酸アンモニウム含有溶液を調製する工程と、0.1~4重量%のカルシウム塩含有溶液を調製する工程と、前記アルギン酸カリウム含有溶液及び前記カルシウム塩含有溶液の一方を他方に添加する工程と、を含む。 The method for producing a sodium adsorbent solid product of the present invention includes the steps of preparing a solution containing 0.1 to 5% by weight of potassium alginate or ammonium alginate, and preparing a solution containing 0.1 to 4% by weight of a calcium salt. and adding one of the potassium alginate-containing solution and the calcium salt-containing solution to the other.
本発明の排塩用食品組成物は、本発明の方法により得られるナトリウム吸着性固形状物を含む。 The food composition for salt removal of the present invention contains a sodium adsorbent solid obtained by the method of the present invention.
本発明の排塩用食品組成物は、アルギン酸カルシウム等の既存のアルギン酸塩類よりも優れたナトリウム吸着性を有すると共に、既存のアルギン酸塩類よりも食感に優れている。よって、本発明の排塩用食品組成物は、摂取が容易であると共に、ナトリウムの排出を促進して、ナトリウムの過剰摂取による健康障害を予防又は改善することができる。本発明のナトリウム吸着性固形状物の製造方法によれば、ナトリウム吸着性及び食感に優れたナトリウム吸着性固形状物を得ることができる。 The food composition for salt removal of the present invention has better sodium adsorption than existing alginates such as calcium alginate, and has better texture than existing alginates. Therefore, the salt excretion food composition of the present invention is easy to ingest, promotes sodium excretion, and can prevent or improve health disorders caused by excessive sodium intake. According to the method for producing a sodium adsorbent solid product of the present invention, a sodium adsorbent solid product having excellent sodium adsorption properties and texture can be obtained.
本発明のナトリウム吸着性固形状物(以下、「本固形状物」という。)の製造方法(以下、「本方法」という。)は、0.1~5重量%のアルギン酸カリウム又はアルギン酸アンモニウム含有溶液を調製する工程と、0.1~4重量%のカルシウム塩含有溶液を調製する工程と、前記アルギン酸カリウム含有溶液及び前記カルシウム塩含有溶液の一方を他方に添加する工程と、を含む。 The method for producing a sodium-adsorbing solid material (hereinafter referred to as "this solid material") of the present invention (hereinafter referred to as "this method") contains 0.1 to 5% by weight of potassium alginate or ammonium alginate. The method includes the steps of preparing a solution, preparing a solution containing 0.1 to 4% by weight of a calcium salt, and adding one of the potassium alginate-containing solution and the calcium salt-containing solution to the other.
前記アルギン酸カリウム及びアルギン酸アンモニウムは、D-マンヌロン酸とL-グルロン酸という2種類のウロン酸が直鎖状に重合した、生分解性の高分子多糖類であるアルギン酸中のカルボキシル基の水素原子がカリウム又はアンモニウムとイオン交換することで得られる塩である。前記アルギン酸カリウム及びアルギン酸アンモニウムの分子量には特に限定はない。また、前記アルギン酸カリウム及びアルギン酸アンモニウムは、化学構造の一部を置換ないし修飾したものでもよい。前記アルギン酸カリウムは、1種単独でもよく、あるいは分子量又は化学構造が一部異なるアルギン酸カリウムの2種以上を用いてもよい。同様に、前記アルギン酸アンモニウムは、1種単独でもよく、あるいは分子量又は化学構造が一部異なるアルギン酸アンモニウムの2種以上を用いてもよい。 The above-mentioned potassium alginate and ammonium alginate are biodegradable polymeric polysaccharides in which two types of uronic acids, D-mannuronic acid and L-guluronic acid, are linearly polymerized. It is a salt obtained by ion exchange with potassium or ammonium. There is no particular limitation on the molecular weight of the potassium alginate and ammonium alginate. Further, the potassium alginate and ammonium alginate may have their chemical structures partially substituted or modified. The potassium alginate may be used alone, or two or more potassium alginates having partially different molecular weights or chemical structures may be used. Similarly, one type of ammonium alginate may be used alone, or two or more types of ammonium alginate having partially different molecular weights or chemical structures may be used.
前記アルギン酸カリウム又はアルギン酸アンモニウム含有溶液中の前記アルギン酸カリウム又はアルギン酸アンモニウムの含有量は0.1~5重量%、好ましくは0.2~4重量%、更に好ましくは0.3~3重量%、より好ましくは0.5~2重量%である。上記の上限値及び下限値は適宜組み合わせることができる。尚、前記アルギン酸カリウム又はアルギン酸アンモニウム含有溶液は、アルギン酸カリウム及びアルギン酸アンモニウムの両者を含む場合、いずれか一方の含有量が上記範囲でもよく、あるいは両者の含有量の合計値が上記範囲でもよい。 The content of the potassium alginate or ammonium alginate in the solution containing potassium alginate or ammonium alginate is 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.3 to 3% by weight, or more. Preferably it is 0.5 to 2% by weight. The above upper limit value and lower limit value can be combined as appropriate. In addition, when the potassium alginate or ammonium alginate-containing solution contains both potassium alginate and ammonium alginate, the content of either one may be within the above range, or the total content of both may be within the above range.
前記アルギン酸カリウム又はアルギン酸アンモニウム含有溶液は、アルギン酸カリウム及びアルギン酸アンモニウムのいずれか一方のみを含んでもよく、アルギン酸カリウム及びアルギン酸アンモニウムの両者を含んでもよい。アルギン酸アンモニウムと比べて、アルギン酸カリウムでは、投与後に遊離したカチオンと他成分との薬物相互作用(例えば、アンモニウムイオンと塩化物イオンとの相互作用による塩化アンモニウムの形成)の影響が低いと考えられる。よって、前記アルギン酸カリウム又はアルギン酸アンモニウム含有溶液として好ましくは、アルギン酸カリウムのみを含む溶液か、あるいはアルギン酸カリウムの含有量がアルギン酸アンモニウムの含有量よりも多い(例えば、アルギン酸カリウムとアルギン酸アンモニウムの質量比が(2~10):1)溶液である。 The solution containing potassium alginate or ammonium alginate may contain only one of potassium alginate and ammonium alginate, or may contain both potassium alginate and ammonium alginate. Compared to ammonium alginate, potassium alginate is thought to be less susceptible to drug interactions between cations released after administration and other components (e.g., the formation of ammonium chloride due to the interaction of ammonium ions and chloride ions). Therefore, the solution containing potassium alginate or ammonium alginate is preferably a solution containing only potassium alginate, or a solution in which the content of potassium alginate is higher than the content of ammonium alginate (for example, the mass ratio of potassium alginate and ammonium alginate is ( 2-10): 1) It is a solution.
前記アルギン酸カリウム含有溶液は、他のアルギン酸塩を更に含んでもよく、含まなくてもよい。他のアルギン酸塩は1種単独でもよく、2種以上を含んでもよい。他のアルギン酸塩として、例えば、アルギン酸ナトリウムが挙げられる。前記他のアルギン酸塩の含有量は必要に応じて適宜設定することができる。前記他のアルギン酸塩の含有量として、例えば、0.01~5重量%、0.05~4重量%、0.1~3重量%、0.5~2.5重量%とすることができる。上記の上限値及び下限値は適宜組み合わせることができる。 The potassium alginate-containing solution may or may not further contain other alginates. One type of other alginate may be used alone, or two or more types may be included. Other alginates include, for example, sodium alginate. The content of the other alginates can be appropriately set as necessary. The content of the other alginates can be, for example, 0.01 to 5% by weight, 0.05 to 4% by weight, 0.1 to 3% by weight, and 0.5 to 2.5% by weight. . The above upper limit value and lower limit value can be combined as appropriate.
前記カルシウム塩は、前記アルギン酸カリウム含有溶液と混合することにより、固化あるいはゲル化反応を起こすものであればよい。前記カルシウム塩は、無機カルシウム塩及び有機カルシウム塩のいずれでもよい。前記有機カルシウム塩は、1価カルボン酸との塩でもよく、2価以上の多価カルボン酸との塩でもよい。有機カルシウム塩として具体的には、例えば、グルコン酸カルシウム、クエン酸カルシウム、乳酸カルシウム、酢酸カルシウム、安息香酸カルシウム、及びステアリン酸カルシウムが挙げられる。前記無機カルシウム塩として具体的には、例えば、塩化カルシウム及び炭酸カルシウムが挙げられる。前記カルシウム塩は1種単独でもよく、2種以上を用いてもよい。 The calcium salt may be any salt that causes a solidification or gelation reaction when mixed with the potassium alginate-containing solution. The calcium salt may be either an inorganic calcium salt or an organic calcium salt. The organic calcium salt may be a salt with a monovalent carboxylic acid or a salt with a polyvalent carboxylic acid having a valence of two or more. Specific examples of organic calcium salts include calcium gluconate, calcium citrate, calcium lactate, calcium acetate, calcium benzoate, and calcium stearate. Specific examples of the inorganic calcium salt include calcium chloride and calcium carbonate. The calcium salt may be used alone or in combination of two or more.
前記アルギン酸カリウム含有溶液中の前記カルシウム塩の含有量は0.1~4重量%、好ましくは0.2~3重量%、更に好ましくは0.3~2重量%である。 The content of the calcium salt in the potassium alginate-containing solution is 0.1 to 4% by weight, preferably 0.2 to 3% by weight, and more preferably 0.3 to 2% by weight.
前記アルギン酸カリウム含有溶液の調製方法には特に限定はない。前記アルギン酸カリウム含有溶液は通常、溶媒を攪拌しながら、アルギン酸カリウムを何回かに分けて少量ずつ加えて溶解させる。これにより、アルギン酸カリウムの溶解を早めることができるので好ましい。前記溶媒は、前記アルギン酸カリウム含有溶液を調製できる限り特に限定はない。前記溶媒は通常、水(蒸留水、滅菌蒸留水)が用いられる。 There are no particular limitations on the method for preparing the potassium alginate-containing solution. The potassium alginate-containing solution is usually dissolved by adding potassium alginate little by little in several portions while stirring the solvent. This is preferable because the dissolution of potassium alginate can be accelerated. The solvent is not particularly limited as long as it can prepare the potassium alginate-containing solution. Water (distilled water, sterile distilled water) is usually used as the solvent.
前記カルシウム塩含有溶液の調製方法には特に限定はない。前記カルシウム塩含有溶液は、例えば、溶媒にカルシウム塩を添加して溶解させることにより得ることができる。前記溶媒は、前記カルシウム塩含有溶液を調製できる限り特に限定はない。前記溶媒は通常、水(蒸留水、滅菌蒸留水)が用いられる。 There are no particular limitations on the method for preparing the calcium salt-containing solution. The calcium salt-containing solution can be obtained, for example, by adding and dissolving a calcium salt in a solvent. The solvent is not particularly limited as long as it can prepare the calcium salt-containing solution. Water (distilled water, sterile distilled water) is usually used as the solvent.
前記アルギン酸カリウム含有溶液及び前記カルシウム塩含有溶液の一方を他方に添加する工程の具体的態様には特に限定はない。通常、前記アルギン酸カリウム含有溶液に前記カルシウム塩含有溶液を添加するが、逆でもよい。また、前記添加は通常、前記アルギン酸カリウム含有溶液及び前記カルシウム塩含有溶液の一方を攪拌しながら、他方を滴下することにより行われる。 There is no particular limitation on the specific embodiment of the step of adding one of the potassium alginate-containing solution and the calcium salt-containing solution to the other. Usually, the calcium salt-containing solution is added to the potassium alginate-containing solution, but the reverse is also possible. Further, the addition is usually performed by dropping one of the potassium alginate-containing solution and the calcium salt-containing solution while stirring the other.
「固形状物」には、前記アルギン酸カリウム含有溶液の流動性が低減している態様の全てが含まれる。前記「固形状物」は、完全な固形物だけでなく、被膜中に液状物を内包するカプセル形状物、あるいは前記アルギン酸カリウム含有溶液がゲル化したゼリー状物が含まれる。尚、「ゼリー状」は、同じ条件で測定した場合に、水よりも粘度が大きいことを意味する。 The "solid material" includes all embodiments in which the fluidity of the potassium alginate-containing solution is reduced. The above-mentioned "solid substance" includes not only a completely solid substance but also a capsule-shaped substance containing a liquid substance in a film, or a jelly-like substance obtained by gelling the potassium alginate-containing solution. Note that "jelly-like" means that the viscosity is higher than that of water when measured under the same conditions.
(2)排塩用食品組成物
本発明の排塩用食品組成物(以下、「本組成物」という。)は、本固形状物を有効量含む。本固形状物については、上記の説明が妥当する。また、前記有効量は、ナトリウム吸着能を奏する量の意味であり、ナトリウム吸着能を奏する限り、前記有効量には特に限定はなく、当業者が適宜設定することができる。また、本組成物は、経口で摂取することができる限り、具体的な形態に特に限定はない。前記「食品」には飲料も含まれる。
(2) Food composition for salt removal The food composition for salt removal of the present invention (hereinafter referred to as "the present composition") contains an effective amount of the present solid material. The above explanation is valid for this solid material. Moreover, the effective amount means an amount that exhibits sodium adsorption ability, and as long as it exhibits sodium adsorption ability, the effective amount is not particularly limited and can be appropriately set by those skilled in the art. Further, the specific form of the composition is not particularly limited as long as it can be taken orally. The above-mentioned "food" also includes drinks.
本組成物は、ヒト又は非ヒト動物のいずれにも投与することができる。前記非ヒト動物の種類には特に限定がない。前記非ヒト動物として具体的には、例えば、イヌ、ネコ、マウス、インコ、モルモット、ハムスター、ラット、フェレット、サル、ウシ、ブタ、ヤギ、ヒツジ、ニワトリが挙げられる。 The composition can be administered to either humans or non-human animals. There are no particular limitations on the type of non-human animal. Specific examples of the non-human animals include dogs, cats, mice, parakeets, guinea pigs, hamsters, rats, ferrets, monkeys, cows, pigs, goats, sheep, and chickens.
本組成物は、上記のようにナトリウム吸着能に優れ、ナトリウム排泄を促進することができる。よって、本組成物は、うっ血性心疾患の改善のために用いることができる。前記「うっ血性心疾患の改善」は、うっ血性心疾患の治療、症状緩和、及び予防(悪化の抑制)を含む。また、本組成物は、血圧及び/又は腎機能の改善のために用いることができる。前記「血圧及び/又は腎機能の改善」には、状態の変化だけでなく、正常な状態の維持も含む。例えば、血圧の改善には、血圧の低下及び正常な血圧の維持が含まれる。同様に、腎機能の改善には、腎機能障害の改善及び正常な腎機能の維持が含まれる。また、本組成物は、うっ血性心疾患の改善のために用いることができる。 As mentioned above, the present composition has excellent sodium adsorption ability and can promote sodium excretion. Therefore, the present composition can be used to improve congestive heart disease. The above-mentioned "improvement of congestive heart disease" includes treatment, symptom relief, and prevention (suppression of deterioration) of congestive heart disease. Additionally, the present composition can be used to improve blood pressure and/or renal function. The above-mentioned "improvement of blood pressure and/or renal function" includes not only a change in condition but also maintenance of a normal condition. For example, improving blood pressure includes lowering blood pressure and maintaining normal blood pressure. Similarly, improving renal function includes improving renal dysfunction and maintaining normal renal function. The composition can also be used to improve congestive heart disease.
本組成物は、本固形状物のみで構成されていてもよく、他の成分を更に含んでいてもよい。前記他の成分として、飲食品成分(例えば、肉類(牛、豚等)、魚介類、果物)の他、従来からヒト又は非ヒト動物用の食品(飼料を含む。)及び医薬に含有することが公知となっている成分(例えば、糖類、アミノ酸、pH調整剤、ビタミン、酸化防止剤、色素、防腐剤、及び香料等)が挙げられる。前記他の成分の含有量は必要に応じて適宜設定することができる。例えば、前記他の成分、特に前記飲食品成分の含有量は1~40重量%、好ましくは3~20重量%、更に好ましくは5~15重量%とすることができる。 The present composition may be composed only of the present solid material, or may further contain other components. In addition to food and drink components (e.g., meat (cow, pig, etc.), seafood, fruits), the other ingredients may be conventionally contained in foods (including feed) and medicines for humans or non-human animals. Examples include known components (eg, saccharides, amino acids, pH adjusters, vitamins, antioxidants, pigments, preservatives, fragrances, etc.). The content of the other components can be appropriately set as necessary. For example, the content of the other components, particularly the food/drink components, can be 1 to 40% by weight, preferably 3 to 20% by weight, and more preferably 5 to 15% by weight.
一方、本組成物は、アルギン酸カルシウムを含まなくてもよい。本組成物は、クエン酸を含まなくてもよい。本組成物は他の熱不可逆性ゲルを形成しうる水溶性高分子(例えば、ペクチン、CMC及びジェランガム等の他の多糖類)を含まなくてもよい。尚、「含まない」とは、完全に含まない態様に加え、食感及びナトリウム吸着能に影響を与えない微量(例えば、0.01重量%以下、0.005重量%以下、0.001重量%以下で下限値は0を超える量)を含む態様も含む。 On the other hand, the composition may not contain calcium alginate. The composition may be free of citric acid. The composition may be free of other heat-irreversible gel-forming water-soluble polymers (eg, pectin, CMC, and other polysaccharides such as gellan gum). In addition, "not containing" means not containing completely, but also containing a trace amount that does not affect the texture and sodium adsorption capacity (for example, 0.01% by weight or less, 0.005% by weight or less, 0.001% by weight) % or less and the lower limit exceeds 0).
<不可能・非実際的事情について>
後述の実施例より、本組成物は、単なるアルギン酸カルシウムよりも優れたNa除去効果を示す。このことは、本組成物が、単にアルギン酸カリウムとカルシウムとが反応して形成されるアルギン酸カルシウムを主成分とするものではないことを示している。しかし、本方法によるアルギン酸カリウムとカルシウム塩の化学的・物理的変化、及び変化後の構造、形態とナトリウムの除去効果との関係を調べて、本固形状物を構造・特性の点から具体的に明確にすることは、不可能であるか、著しい時間、費用が必要であり、非実際的である。発明者の推定として、アルギン酸カリウムは、例えるなら長い糸の途中に等間隔で釣り針がぶら下がっており、それが何本もあるため、ナトリウムと触れると釣り針のいくつかに引っかかって吸着し得るところ、アルギン酸カリウムにカルシウム塩を添加すると、カルシウムが媒体となってゲル化し、独立していた釣り針の糸がいわゆる網の目状になるため、更にナトリウムを吸着し易くなったと考えられる(尚、これは発明者の推定に過ぎず、何ら本願発明を特定又は定義する趣旨の説明ではない。)。
<About impossible/impractical circumstances>
From the examples described later, this composition shows a superior Na removal effect than simple calcium alginate. This indicates that the present composition does not consist primarily of calcium alginate, which is formed simply by the reaction of potassium alginate and calcium. However, by investigating the chemical and physical changes in potassium alginate and calcium salts caused by this method, as well as the relationship between the structure and form after the change and the sodium removal effect, we have determined that this solid product can be used in specific terms in terms of structure and properties. It is either impossible or requires significant time, expense, and impractical to provide clarity. The inventor estimates that potassium alginate, for example, has many fishing hooks hanging at equal intervals along the middle of a long string, so when it comes into contact with sodium, it can get caught on some of the fishing hooks and be adsorbed. When calcium salts were added to potassium alginate, the calcium became a medium and gelled, and the independent fishing hook threads became so-called mesh-like, making it easier to adsorb sodium. (This is merely an estimate by the inventor, and is not intended to specify or define the claimed invention in any way.)
以下、実施例により本発明を具体的に例示する。尚、本発明は、実施例に示す形態に限定されない。本発明の実施形態は、目的及び用途に応じて、本発明の範囲内で種々変更することができる。尚、実施例における結果に対する考察は、全て発明者の見解に過ぎず、何ら本願発明を定義ないし限定する趣旨の説明ではないことを付言する。 Hereinafter, the present invention will be specifically illustrated with reference to Examples. Note that the present invention is not limited to the embodiments shown in the examples. The embodiments of the present invention can be modified in various ways within the scope of the present invention depending on the purpose and use. It should be noted that all considerations regarding the results in the Examples are merely the opinions of the inventors, and are not intended to define or limit the present invention in any way.
(1)排塩組成物の合成(I)-粒状形態
滅菌蒸留水(19g)をスターラーにより500~1200rpmで攪拌しながらフレーバー(1.0g)を加え、5%フレーバー溶液を調製した。次いで、1200rpmで攪拌しながら、アルギン酸カリウム(0.4g)を少量ずつ、前記溶液に加えて約15分程度攪拌を続け、アルギン酸カリウムが溶解したことを確認して、アルギン酸カリウム溶液(20ml)を調製した。
(1) Synthesis of waste salt composition (I) - Granular form Flavor (1.0 g) was added to sterile distilled water (19 g) while stirring with a stirrer at 500 to 1200 rpm to prepare a 5% flavor solution. Next, while stirring at 1200 rpm, add potassium alginate (0.4 g) little by little to the solution and continue stirring for about 15 minutes. After confirming that the potassium alginate has dissolved, add the potassium alginate solution (20 ml). Prepared.
5%グルコン酸カルシウム溶液(5ml)を水道水37.5mlに溶解させて、1%グルコン酸カルシウム溶液を調製した。該溶液をスターラーにより250rpmで攪拌し、該溶液に前記アルギン酸カリウム溶液を100ml/hの速度で加えた。得られた粒状物をろ過し、水洗し、風乾させて、粒状形態の組成物を得た。 A 1% calcium gluconate solution was prepared by dissolving 5% calcium gluconate solution (5 ml) in 37.5 ml of tap water. The solution was stirred at 250 rpm using a stirrer, and the potassium alginate solution was added to the solution at a rate of 100 ml/h. The resulting granules were filtered, washed with water, and air-dried to obtain a composition in granular form.
(2)排塩組成物の合成(II)-ゼリー状形態
アルギン酸カリウム2.0g及びクエン酸カルシウム0.6gを乳鉢で均等になるまで混和して、混和物を得た。次いで、鶏挽肉20gを蒸留水(200ml)に混合し、この中に前記混和物を少量ずつ加えて溶解させて、1%アルギン酸カリウム含有溶液を調製した。前記溶液をレトルト包装内に注入し、85℃~120℃で滅菌(レトルト滅菌の方法に準じる)し、室温下で3~12時間静置して、ゼリー状形態の組成物(レトルト包装;10g/包)を得た。
(2) Synthesis of waste salt composition (II) - Jelly form 2.0 g of potassium alginate and 0.6 g of calcium citrate were mixed in a mortar until they were evenly mixed to obtain a mixture. Next, 20 g of ground chicken meat was mixed with distilled water (200 ml), and the mixture was added little by little to the mixture to dissolve it, thereby preparing a solution containing 1% potassium alginate. The solution is injected into a retort package, sterilized at 85°C to 120°C (according to the retort sterilization method), and left to stand at room temperature for 3 to 12 hours to obtain a jelly-like composition (retort package; 10g). / package) was obtained.
(3)ナトリウム吸着量の測定
医療用生理食塩水(Na:154mEq/L)20mlに、上記排塩組成物(粒状形態;50、100、及び150mg)をすりつぶして加えた。その後、塩分濃度計(HORIBA社製)により、水溶液中の塩化ナトリウムの濃度(%)を測定した。対照として、上記生理食塩水を用いた。その結果を表1及び図1に示す。尚、吸着率(%)は、以下の式により求めた
(3) Measurement of sodium adsorption amount The above salt removal composition (granular form; 50, 100, and 150 mg) was ground and added to 20 ml of medical saline (Na: 154 mEq/L). Thereafter, the concentration (%) of sodium chloride in the aqueous solution was measured using a salinity meter (manufactured by HORIBA). As a control, the above physiological saline was used. The results are shown in Table 1 and FIG. The adsorption rate (%) was calculated using the following formula.
(A)上記排塩組成物(粒状形態)、(B)アルギン酸アンモニウム、(C)「デルソル」(トイメディカル社製;アルギン酸類として、アルギン酸カルシウム及びアルギン酸アンモニウムを含み、且つアルギン酸カリウムを含まない。)、及び(D)アルギン酸カルシウムをそれぞれ120mgとり、それぞれをすりつぶして医療用生理食塩水(Na:154mEq/L)20mlに加えた。対照として、上記生理食塩水を使用した。対照及び(A)~(D)について、それぞれ3個のサンプルを準備した。その後、動物用血液測定器「ドライケムMX700」(富士フイルム社製)でサンプルのNa濃度(mEq/L)を測定した。その結果を表2及び図2に示す。 (A) the above-mentioned waste salt composition (granular form), (B) ammonium alginate, (C) "Delsol" (manufactured by Toy Medical Co., Ltd.; contains calcium alginate and ammonium alginate as alginic acids, and does not contain potassium alginate. ) and (D) 120 mg of calcium alginate were each taken, ground and added to 20 ml of medical saline (Na: 154 mEq/L). As a control, the above physiological saline was used. Three samples each were prepared for the control and (A) to (D). Thereafter, the Na concentration (mEq/L) of the sample was measured using an animal blood measuring device "Drychem MX700" (manufactured by Fujifilm). The results are shown in Table 2 and FIG.
(4)結果
表1及び図1より、実施例の組成物を加えることにより、約15~42%の塩分削減が認められた。
(4) Results From Table 1 and FIG. 1, by adding the compositions of Examples, a reduction in salt content of about 15 to 42% was observed.
また、表2及び図2より、アルギン酸アンモニウム、「デルソル」(アルギン酸類として、アルギン酸カルシウム及びアルギン酸アンモニウムを含み、且つアルギン酸カリウムを含まない。)、及びアルギン酸カルシウムはいずれも、塩分削減が10%程度であるのに対し、実施例の組成物では、約40%の塩分削減を示した。特に、アルギン酸カルシウムと比較して、実施例の組成物が優れた塩分削減を示しているこの結果は、実施例の組成物が、物質として、単なるアルギン酸カルシウムとは異なることを示している。 In addition, from Table 2 and Figure 2, ammonium alginate, "Delsol" (contains calcium alginate and ammonium alginate as alginic acids, but does not contain potassium alginate), and calcium alginate all have a salt reduction of about 10%. On the other hand, the composition of the example showed a salt reduction of about 40%. In particular, this result showing superior salt reduction for the example compositions compared to calcium alginate indicates that the example compositions are different from just calcium alginate as a substance.
Claims (4)
0.1~4重量%のカルシウム塩含有溶液を調製する工程と、
前記アルギン酸カリウム含有溶液及び前記カルシウム塩含有溶液の一方を他方に添加する工程と、を含む、ナトリウム吸着用固形状物の製造方法。 Preparing a solution containing 0.1 to 5% by weight of potassium alginate or ammonium alginate;
Preparing a solution containing 0.1 to 4% by weight of calcium salt;
A method for producing a solid material for adsorbing sodium, comprising the step of adding one of the potassium alginate-containing solution and the calcium salt-containing solution to the other.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022058332A JP7369819B2 (en) | 2022-03-31 | 2022-03-31 | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022058332A JP7369819B2 (en) | 2022-03-31 | 2022-03-31 | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023149652A JP2023149652A (en) | 2023-10-13 |
JP7369819B2 true JP7369819B2 (en) | 2023-10-26 |
Family
ID=88288713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022058332A Active JP7369819B2 (en) | 2022-03-31 | 2022-03-31 | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7369819B2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657869A (en) | 2012-05-25 | 2012-09-12 | 无锡福尔顺科技有限公司 | Alginate hard capsule disintegrable at different positions in gastrointestinal tract |
CN108142874A (en) | 2017-11-30 | 2018-06-12 | 青岛明月海藻生物科技有限公司 | A kind of wide powder of health care seaweed and preparation method thereof |
JP2019013220A (en) | 2017-07-03 | 2019-01-31 | トイメディカル株式会社 | Food composition aiming at sodium excretion |
JP2023039734A (en) | 2021-09-09 | 2023-03-22 | 伊那食品工業株式会社 | Food material and production method of the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60130523A (en) * | 1983-12-16 | 1985-07-12 | Yamasa Shoyu Co Ltd | Medical food additive and food containing the same |
US4880654A (en) * | 1986-12-22 | 1989-11-14 | Minoru Okada | Process for preparing simulated meat |
-
2022
- 2022-03-31 JP JP2022058332A patent/JP7369819B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657869A (en) | 2012-05-25 | 2012-09-12 | 无锡福尔顺科技有限公司 | Alginate hard capsule disintegrable at different positions in gastrointestinal tract |
JP2019013220A (en) | 2017-07-03 | 2019-01-31 | トイメディカル株式会社 | Food composition aiming at sodium excretion |
CN108142874A (en) | 2017-11-30 | 2018-06-12 | 青岛明月海藻生物科技有限公司 | A kind of wide powder of health care seaweed and preparation method thereof |
JP2023039734A (en) | 2021-09-09 | 2023-03-22 | 伊那食品工業株式会社 | Food material and production method of the same |
Also Published As
Publication number | Publication date |
---|---|
JP2023149652A (en) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60118893T2 (en) | INSULIN PRODUCTS WITH IMPROVED FOOD PROPERTIES | |
JP4047363B1 (en) | Gel enteral nutrient | |
US9402808B2 (en) | Liquid oral composition of lanthanum salts | |
JP4652486B2 (en) | Formulation for oral administration containing chondroitin sulfate-containing cartilage aqueous solvent extract and quercetin glycoside | |
DE3228231A1 (en) | MEDICINAL PRODUCTS, CALCIUM MIXED SALTS OF POLYMERS, ANIONIC CARBONIC ACIDS AND / OR SULFURIC ACID ESTERS, PROCESS FOR THEIR PRODUCTION AND THEIR USE | |
KR20090115936A (en) | Diet product comprising alginate | |
TW200916107A (en) | Calcium absorption enhancer | |
JP7369819B2 (en) | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material | |
JPWO2005120458A1 (en) | Composition for oral ingestion in dry form and composition for gel ingestion prepared at the time of use | |
JP5106948B2 (en) | Oral administration adjuvant composition for pets | |
JP5090848B2 (en) | Method for producing gel composition | |
JP5436895B2 (en) | Oral formulation containing water-extracted chondroitin and milk flavor | |
US10945964B2 (en) | Microencapsulated chitosan, methods of making and methods for the use thereof | |
JP2008094743A (en) | Ingesting/swallowing ameliorating food | |
US20200275686A1 (en) | Food composition for the preparation of products for subjects with swallowing difficulty and use thereof in automated dispensing machines | |
CN101027063B (en) | Use of difructose anhydride for preparation drug | |
CN107404918B (en) | Jelly composition and food | |
JPH07118162A (en) | Oral administration composition for livestock | |
EP3675649B1 (en) | Compositions for increasing intake of water in felines | |
SE522529C2 (en) | Effervescent solid composition used for treating dermal wounds comprises chitosan or component releasing carbon dioxide in acidic environment | |
JP6866011B2 (en) | Jelly agent composition and foods containing the jelly agent composition | |
JP2007236222A (en) | Composition containing chitosan and slightly soluble salt | |
JPWO2004096243A1 (en) | Constipation prevention and improvement agent | |
JP6206420B2 (en) | Method for producing gel composition containing ferric citrate at high concentration | |
JPH0352691A (en) | Acid-containing water |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230721 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230919 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231016 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7369819 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |